Skip to main content
Clinical Trials/ISRCTN95468513
ISRCTN95468513
Active, not recruiting
未知

Promoting rational antibiotic therapy among high antibiotic prescribers in German primary care (ElektRA). A 4-arm cluster-randomised controlled trial

Association of Substitute Health Funds (Vdek) e.V.0 sites7,250 target enrollmentJuly 22, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Acute respiratory and urinary tract infections
Sponsor
Association of Substitute Health Funds (Vdek) e.V.
Enrollment
7250
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36195897/ (added 06/10/2022)

Registry
who.int
Start Date
July 22, 2022
End Date
December 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Association of Substitute Health Funds (Vdek) e.V.

Eligibility Criteria

Inclusion Criteria

  • 1\. General practitioners (GP)
  • 2\. Registered as physician with the Association of Statutory Health Insurance Physicians located in Baden\-Wuerttemberg, Bavaria, Bremen, Hesse, Lower Saxony, North Rhine, Saarland, Schleswig\-Holstein, Westphalia\-Lippe
  • 3\. Prescription sum score \>2 (sum score ranges from 0 to 6; a GP or GP practice obtains one or two points if its own value in one of the following aspects exceeds the 75% percentile of antibiotic prescribing within the respective region:
  • 3\.1\. Overall prescription rate (ratio of patients with antibiotic prescriptions to patients with any prescription), one point
  • 3\.2\. Prescription rate for upper respiratory tract infections (ratio of patients with upper respiratory tract infection to antibiotic prescriptions for these patients), one point
  • 3\.3\. Prescription rate for lower respiratory tract infections (ratio of patients with lower respiratory tract infection to antibiotic prescriptions for these patients), one point
  • 3\.4\. Prescription rate of fluoroquinolones; two points: Total prescription rate of fluoroquinolones (ratio of patients with fluoroquinolone to patients with antibiotic) and/or fluoroquinolone prescription rate for urinary tract infection (ratio of urinary tract infection patients with fluoroquinolone to urinary tract infection patients with antibiotics
  • 3\.5\. Prescription rate of cephalosporins (ratio of patients with cephalosporin to patients with antibiotic); one point

Exclusion Criteria

  • Participation on the predecessor project RESIST

Outcomes

Primary Outcomes

Not specified

Similar Trials